Lyka Labs Ltd

At Rs 62.47, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Lyka Labs Ltd locked at its upper circuit of 5% on 7 May 2026, with buyers queuing and no sellers willing to part with shares.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 Jan 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 07 May 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics presented here reflect the stock’s current position as of 26 April 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 April 2026, providing investors with the latest insights into the company’s performance and outlook.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 12 January 2026, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are current as of 04 April 2026, providing investors with the latest comprehensive view of the company’s position.

Despite a broader market recovery, Lyka Labs Ltd has plunged to a fresh 52-week low of Rs 44.55 on 30 Mar 2026, marking a steep 53.37% decline over the past year and underscoring persistent headwinds for this micro-cap pharmaceutical player.

While broader indices showed signs of recovery, Lyka Labs Ltd plunged to a fresh 52-week low of Rs 47.3 on 27 Mar 2026, marking a steep decline of 7.74% intraday and underperforming its sector by over 7%. This drop extends the stock’s downward trajectory amid persistent financial headwinds and market scepticism.

Despite a broadly positive market environment, Lyka Labs Ltd has plunged to a fresh 52-week low of Rs 47.7 on 24 Mar 2026, extending its recent downward trajectory amid persistent headwinds.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 March 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Lyka Labs Ltd’s share price declined sharply on 23 Mar 2026, hitting a new 52-week low of Rs.50.09. This marks a significant drop for the pharmaceutical and biotechnology company, reflecting ongoing pressures both within the stock and the broader market environment.

Lyka Labs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, recorded a fresh 52-week low of Rs.51.17 on 17 Mar 2026, marking a significant decline amid persistent underperformance and deteriorating financial metrics.

Lyka Labs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.51.45 today, marking a significant decline in its stock price amid ongoing financial and market pressures. This fresh low underscores the stock’s persistent underperformance relative to its sector and benchmark indices.

Lyka Labs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.54 today, marking a significant decline amid ongoing market pressures and company-specific headwinds. The stock has underperformed its sector and benchmark indices, reflecting persistent challenges in its financial and technical performance.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, all fundamentals, returns, and financial metrics discussed here reflect the stock’s current position as of 12 March 2026, providing investors with the latest comprehensive analysis.

Lyka Labs Ltd’s shares declined to a fresh 52-week low of Rs.55 on 11 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent pressures on the company’s valuation amid subdued financial performance and broader market headwinds.

Lyka Labs Ltd’s share price declined to a fresh 52-week low of Rs.56 on 10 Mar 2026, marking a significant milestone in the stock’s ongoing downward trajectory. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges that have weighed on investor sentiment.

Lyka Labs Ltd’s share price has declined to a fresh 52-week low, closing just 0.7% above its lowest level of Rs 56.6. The stock’s recent performance reflects ongoing pressures within the Pharmaceuticals & Biotechnology sector, with the company’s shares underperforming both the sector and broader market indices.

Lyka Labs Ltd has reached a 52-week low, with its share price touching Rs 60.59 on 2 Mar 2026, marking a significant decline amid ongoing pressures in the Pharmaceuticals & Biotechnology sector. The stock’s recent performance reflects a continuation of a downward trend, with multiple factors contributing to its current valuation.

Lyka Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 12 January 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 27 February 2026, providing investors with the latest insights into the company’s performance and outlook.